Kornimate/medical-research-clean huggingface dataset:
baff and april and response to belimumab in sle

Conditions: Systemic Lupus Erythematosus; BAFF Polymorphism

Summary: this project is intended to identify the routes on which baff and april act in order to detect possible future candidates to belimumab treatment among patients diagnosed of sle.

design establish the influence of certain polymorphisms in the levels of expression of different transcripts and proteins. quantify the levels of b cell activating factor belonging to the tnf family (baff) and a proliferation-inducing ligand (april) in serum and urine of patients and controls by enzyme-linked immunosorbent assay (elisa). baff determine the expression levels of different baff and april transcripts in peripheral blood mononuclear cells from patients and controls using a digital pcr (polymerase chain reaction) system. compare distribution of gene polymorphisms in baff and april in patients and controls. by sequencing the exome of the ligand and receptor genes using next generation sequencing (ngs). correlate the transcript and protein levels with clinical manifestations and disease activity. the results of the quantification of anti- double-stranded deoxyribonucleic acid.(dsdna) antibody levels tests will be recorded together with those demographics, clinical-epidemiological and response to the treatment.data.

Eligibility criteria:
inclusion criteria * women18-60 years old * for patients only treated with conventional drugs (without immunosuppressive or biological treatment ) * for healthy controls: no autoimmune diseases (blood donors) diagnoses
posterior tibia nerve neuroprolotherapy for dysmenorrhea

Conditions: Dysmenorrhea; Prolotherapy

Summary: the goal of this crossover study is to assessed the treatment efficacy of posterior tibia nerve neuroprolotherapy on dysmenorrhea. the primary outcome is the improvement of visual analogue scale. the main question it aims to answer is: •could the posterior tibial nerve neuroprolotherapy alleviate the pain of dysmenorrhea. participants will be randomly allocated into two groups, group-1 will receive neuroprolotherapy in the first 2 menstrual cycles followed by oral acetaminophen(500mg) for the subsequent 2 menstrual cycles. group02 will received oral acetaminophen(500mg) in initial 2 menstrual cycles, followed by receiving neuroprolotherapy for the subsequent 2 menstrual cycles.

this trial is a crossover study involving the enrollment of 60 women aged 20-50 who experience normal menstrual cycles accompanied by menstrual pain. these participants will be randomly allocated into two distinct groups. in group-1, posterior tibial nerve neuroprolotherapy will be administered during the first two menstrual cycles, followed by oral acetaminophen (500mg) for the subsequent two menstrual cycles. conversely, in group-2, oral acetaminophen (500mg) will be given during the initial two menstrual cycles, followed by a transition to posterior tibial nerve neuroprolotherapy for the last two menstrual cycles. the primary outcome measure for this trial is the improvement in the visual analog scale (vas). secondary outcomes include an assessment of changes in quality of life before and after treatment, as evaluated using the sf-36 questionnaire. furthermore, pulse diagnosis instruments will be employed to analyze alterations in meridian energy before and after treatment.

Eligibility criteria:
inclusion criteria: * women aged 18-50 who experience normal menstrual cycles accompanied by menstrual pain exclusion criteria: * malignant tumors requiring treatment. * pregnant * those who have other acute and chronic pain and are receiving relevant drug treatment. * those who are allergic to acetaminophen or have contraindications. * those who use hormonal contraceptives at the same time. * those with coagulation disorders or taking anticoagulant drugs.

Keywords: dysmenorrhea prolotherapy
the role of immune semaphorins in steatotic liver disease and sepsis

Conditions: Steatosis of Liver; Sepsis; Immune Response

Summary: the impact of the complex liver immunological network on sepsis outcome is largely unknown. steatotic liver disease (sld) is the most common chronic liver disease with prevalence of 25% in european countries. the question remains whether patients with sld are more prone to bacterial infections and what is the impact of persistent liver inflammation to the systemic response to infection, sepsis course and outcomes. semaphorins are a large family of secreted and membrane-bound biological response modifiers present in many organ systems that are associated with sld and development of fibrosis, but also might regulate systemic immune responses in sepsis. this study will investigate the association of semaphorins with sepsis outcomes in patients with sld.

the liver, with its ability to produce acute phase proteins, complement and cytokines, plays a central role in regulating inflammation. a balanced pro- and anti-inflammatory liver response results in bacterial clearance and resolution of inflammation. steatotic liver disease (sld) is the most common chronic liver disease associated with systemic changes in immune response. although there are numerous immunological links between sepsis and sld, there is a significant gap in knowledge regarding the role of sld in sepsis. semaphorins were recently recognized as one of the key regulators of immune responses; while some suppress immune cells activation, proliferation and production of inflammatory cytokines, others stimulate immune responses. semaphorins were recently shown to be associated with pathogenesis of viral hepatitis, sld and progression of fibrosis. however, their role in sepsis is unknown. the hypothesis of this project is that semaphorins are regulators of inflammation in patients with sld that have impact on sepsis outcome.

Eligibility criteria:
inclusion criteria: * 2 or more sirs (systemic inflammatory response syndrome) criteria (1. hyperthermia \>38.3°c or hypothermia \ 90 bpm; 3. tachypnea \>20 bpm; 3. leukocytosis (\>12,000 μl-1) or leukopenia (\<4,000 μl-1)) * clinical suspicion of sepsis * enrolled within 24 hours of hospital admission exclusion criteria: * no consent * immunosuppression * malignancies * immune diseases * pregnancy * hiv infection * presence of chronic liver disease * consumption of alcohol \> 20 g/day
introduction and influence of total mesorectal excision (tme) in the treatment of rectal cancer

Conditions: Rectal Cancer

Summary: total mesorectal excision (tme) is a rather new operation technique in the treatment of rectal cancer. it is known to reduce the rate of local recurrences. however, the influence on long-term survival is unclear.

background the tme technique for rectal cancer surgery was introduced in our department in summer 1995. tme is known to reduce the rate of local recurrences. however, its influence on long-term survival in unclear. all patients with rectal cancer from 1993 to 2001 are reviewed. the patients charts are reviewed and the following main characteristics are retrieved: age, gender, time of operation, operation technique, tumor stage, tumor localisation, tumor size, neoadjuvant or adjuvant treatment, complications, follow-up with respect to the appearance of local recurrences and distant metastases. comparison of two groups of patients. group 1: patients operated before summer 1995, that is before the introduction of tme. group 2: patients operated after summer 1995, that is after the introduction of tme. objective study the influence of a new operation method (tme) on outcome (local recurrence, survival). methods all patients with rectal cancer from 1993 to 2001 are reviewed. the patients charts are reviewed and the following main characteristics are retrieved: age, gender, time of operation, operation technique, tumor stage, tumor localisation, tumor size, neoadjuvant or adjuvant treatment, complications, follow-up with respect to the appearance of local recurrences and distant metastases. comparison of two groups of patients. group 1: patients operated before summer 1995, that is before the introduction of tme. group 2: patients operated after summer 1995, that is after the introduction of tme.

Eligibility criteria:
inclusion criteria: * adenocarcinoma of the rectum * 16 years and older

Keywords: rectal cancer colorectal surgery surgery local neoplasm recurrence survival follow-up study
kid cards: teaching kids about medicines

Conditions: Hemophilia; Sickle Cell Disease; Neoplasms; Blood Coagulation Disorders

Summary: this study is being done to see if education about medicines directed toward children will improve their knowledge. the investigators also want to know if this knowledge lasts over time. right now there are few medication instructional cards that are appropriate for children. most of the medication cards provide information for adults. some studies have shown that by teaching children directly, the children may take medicine at the right time for the right reason, have fewer side effects and know more about their medicine. the purpose of this research study is to see if education about medication helps children learn more about their medicine and if this knowledge lasts.

in 2004, then surgeon general carmona stated that a health literate individual is more apt to know the answer, when asked how to keep themselves well (ahrq, 2004). there is a burgeoning movement among medical professionals to address health literacy. teaching health information to children will empower them to actively participate in their current care and provide self-management skills that will assist them to keep themselves well throughout their lives. currently, few medication administration instructional cards exist that are appropriate for children. providing medication information that the child might understand may result in better administration compliance, fewer adverse effects and develop an individual that is knowledgeable regarding medications and appropriate administration. the purpose if this research is to develop medication administration cards, appropriate for children, which provide information on the most commonly used drugs among the hematology/oncology population. the overall objective of this research is to develop medication informational cards for medications frequently used within the hematology/oncology pediatric population, and evaluate the effectiveness of these cards, by means of a pre- and post-test.

Eligibility criteria:
inclusion criteria: * between the ages of 7 - 11 years * currently receiving disease management primarily coordinated through the hematology/oncology section * receiving a medication identified as a variable for this study * are able to assent and have a parent/guardian who is willing to consent to study participation * suffer no apparent developmental difficulty that would prevent or make study participation difficult exclusion criteria: * individuals who cannot read or write english * individuals who are known to be non-compliant with medication routine and/or adhering to follow-up visits.

Keywords: medication education pediatric
hipec in ovarian cancer, case-controls study with 10-years follow up

Conditions: Ovarian Cancer; HIPEC

Summary: objectives: compare overall survival (os) and progression-free survival (pfs) among ovarian cancer patients who underwent into cytoreduction and hipec procedure vs patients who only received systemic chemotherapy in a 10-years follow up of a case-control study methods: cases were defined as patients treated by cytoreduction and hipec, and were matched (1:2) with patients treated with chemotherapy only, defined as controls. pfs and os in the two groups were measured and compared. pfs was calculated from initiation of treatment to progression, death or to the last known follow-up. os was calculated from initiation of treatment to death or to the last known follow-up.

epithelial ovarian cancer has the highest mortality of all gynecologic tumors in the world wide. patients are diagnosed with international federation of gynecology and obstetrics (figo) stage iii to iv disease in 75%. the 10-year survival of women with advanced-stage ovarian cancer is 10% to 15% and has not improve in the past 20 years. despite treatment with maximal cytoreductive surgery (crs) and platinum-based chemotherapy, approximately 70% of patients with advanced-stage disease relapse within 18 months. given this high number of recurrences, new approaches are needed to improve outcomes for these patients. historically, peritoneal carcinomatosis represents a devastating form of cancer progression with a very poor prognosis. objectives: compare overall survival (os) and progression-free survival (pfs) among ovarian cancer patients who underwent into cytoreduction and hipec procedure vs patients who only received systemic chemotherapy in a 10-years follow up of a case-control study methods: cases were defined as patients treated by cytoreduction and hipec, and were matched (1:2) with patients treated with chemotherapy only, defined as controls. pfs and os in the two groups were measured and compared. pfs was calculated from initiation of treatment to progression, death or to the last known follow-up. os was calculated from initiation of treatment to death or to the last known follow-up.

Eligibility criteria:
inclusion criteria: * diagnosis of epithelial ovarian cancer confirmed * figo stage iii-iv or carcinomatosis recurrence * no comorbidities or controlled comorbidities * ecog 0-2 exclusion criteria: * without carcinomatosis

Keywords: hipec
pharmacokinetics of advantage arrest in healthy children 13-months to 13-years of age

Conditions: Dental Caries in Children

Summary: the purpose of this study is to further characterize basic pharmacokinetic (pk) parameters in healthy children to contribute to evidence for the safety of silver diamine fluoride (sdf; advantage arrest). children with at least one active cavity will be treated and then have blood draws at random time points afterwards.

the fda requested additional data to evaluate the pharmacokinetics of silver diamine fluoride (sdf, advantage arrest) in children 13 months to 13 years old. the first request is for children under 36 months of age to be included in a study. the second request is for serum silver concentration be evaluated for a longer duration post-application to better estimate the half-life of silver and return of serum silver to baseline levels in children.

Eligibility criteria:
inclusion criteria: * at least one untreated caries lesion into the dentin * live within 10 miles of study site exclusion criteria: * oral mucositis * ulcerative oral lesions * hypersensitivity to silver or fluoride * history of treatment with silver diamine fluoride within 3 months

Keywords: pharmacokinetics
testing the validity of the "modified confusion assessment method for the emergency department" (mcam-ed)"

Conditions: Delirium

Summary: the proposed study validates the accuracy of the modified confusion assessment method for the emergency department

delirium is a complex neuropsychiatric syndrome with sudden change in cognition such as disturbance in orientation or memory particularly in elderly patients in the context of acute illness. multiple complications such as falls or increased duration of hospitalisation may result in delirium. long-term consequences may result in increased mortality rates and higher admissions rates to nursing homes. in 2012, delirium prevalence in the emergency department (ed) of the university hospital basel was 9.5% in patients with 65 years and over. although a systematic delirium management was introduced in 2012, without systematic screening delirium detection rates varies between 20 and 40% only. the risk of non-detection over the complete hospitalisation is high when early delirium detection did not occur in the ed. in a preliminary evaluation we could show the usefulness of the mcam-ed

Eligibility criteria:
inclusion criteria: * age \>= 65 years exclusion criteria: * patients under resuscitation or fatal illness * not speaking german * being aphasic * being deaf

Keywords: delirium detection
vitreous inflammation in standard and heavy silicone oil

Conditions: Vitreous Inflammation

Summary: the inflammatory response after prolonged retinal detachment and after vitreoretinal surgery has its apex in the development of pvr that occurs when retinal cells are exposed to the inflammatory milieu in the humor vitreous. this situation is common in complicated retinal detachment, but is amplified after invasive surgery and by the use of intraocular tamponades that float over a subtle film of liquid where the inflammatory cytokines and growth factors reach the critical concentration over the inferior retina. many authors have noted that the heavy tamponade are more prone to cause intraocular inflammation compared to standard silicone oil, especially if they remain for several months in the eye. the purpose of this study is to measure the vitreous concentration of some of the most important cytokines involved in the inflammatory vitreal response.


Eligibility criteria:
inclusion criteria: * patient scheduled for vitrectomy exclusion criteria: * diabetic retinopathy * uveitis
npo and patient satisfaction in the cath lab

Conditions: Patient Satisfaction; Dehydration; Physiological Effects Secondary to Dehydration

Summary: the purpose of this randomized, control study is to compare liberal vs strict nil per os (npo) policies on patients undergoing transcatheter aortic valve replacement (tavr) or arrhythmia ablation. the primary objective of this study is to determine if allowing clear liquids up to 2 hours prior to elective tavr or elective arrhythmia ablation procedure improves patient satisfaction.

after informed written consent, patients will be randomized into one of the two groups: strict npo (npo after midnight) or liberal npo (clear liquids up to 2 hours prior to procedure). all patients, regardless of study arm, will be allowed to take medications with a sip of water. all other peri-operative care will be routine. on the day of the procedure, a patient satisfaction survey will be completed and the procedure will be performed as routine.

Eligibility criteria:
inclusion criteria: * 18 years of age or older, * patients planned to undergo trans-catheter aortic valve replacement or arrhythmia ablation at stony brook university hospital * ability to provide written informed consent exclusion criteria: * age less than 18 years * emergency procedure, dysphasia, nutrition administered via feeding tube (ng, peg, etc.) or intravenously (total parenteral nutrition), gastroparesis, * patients not alert and oriented to person, place, and date, * concurrent surgical procedures on the day of tavr or arrhythmia ablation.

Keywords: nil per os (npo) tavr arrhythmia ablation
the treatment effects of empagliflozin on renal outcomes in cardiorenal syndrome type 1

Conditions: Empagliflozin in Cardiorenal Syndrome Type 1

Summary: effects of empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by make30.


Eligibility criteria:
inclusion criteria * age 18 years or more * hospitalized for the primary diagnosis of acute denovo or decompensated chronic heart regardless of ejection fraction * aki kdigo any stage or urine ngal ≥ 150 ng/ml * must be able to be enrolled into the trial ≤ 12 hours of diagnosis of aki or elevated urine ngal exclusion criteria * denied to participate in the study * cardiogenic shock or unstable hemodynamic (systolic blood pressure of at least 100 mmhg or required inotropic support within last 24 hours) * cardiac mechanical support (i.e. extracorporeal membrane oxygenation and intra-aortic balloon pump) * acute coronary syndrome * diagnosed with cause of aki other than cardiorenal syndrome (eg. sepsis, nephrotoxic, dehydration) * anuria or requiring dialysis or expected to required dialysis within 24 hr * baseline egfr ≤ 20 ml/min/1.73m2 with or without dialysis initiated * heart or kidney transplanted * previously received any sglt2i in the last 3 months before admission * allergic to any sglt2i * type 1 diabetes mellitus * history of ketoacidosis, including diabetic ketoacidosis * pregnancy * comorbid conditions with an expected survival of less than 1 months such as end-stage liver or heart disease, or uncurable malignancy

Keywords: empagliflozin sglt2i cardiorenal syndrome adhf aki
the prospective german non-cf bronchiectasis patient registry

Conditions: Bronchiectasis

Summary: the purpose of this study is to study the epidemiology of non-cf bronchiectasis (ncfb) and to provide an estimate of the distribution (prevalence) of ncfb etiologies across all different levels of health care as well as real-life data regarding the current management of ncfb in germany.

* to study the epidemiology of non-cf bronchiectasis (ncfb) and to provide an estimate of the distribution (prevalence) of ncfb etiologies across all different levels of health care as well as real-life data regarding the current management of ncfb in germany * to establish feasible investigational strategies in order to establish the etiology of ncfb * to perform observational research into bronchiectasis, particularly in areas where single center datasets are underpowered, such as in rare etiologies or determining markers of prognosis * to promote collaborative clinical, basic and translational research in ncfb between german (and european) centers * to provide a registry of well phenotyped patients with ncfb in clinical centers potentially eligible for enrolment into clinical trials * to track access to healthcare and cost of caring for patients with ncfb over time

Eligibility criteria:
inclusion criteria: * a clinical history consistent with bronchiectasis * (high resolution) computed tomography (ct) scan of the chest demonstrating bronchiectasis affecting 1 or more lobes exclusion criteria: * bronchiectasis due to known cystic fibrosis (cf) * age \<18 years * interstitial lung disease * prior lung or heart-lung transplantation

Keywords: prognosis prospective study quality of life radiology rehabilitation registry; signs and symptoms therapy bronchiectiasis diagnosis epidemiology etiology longitudinal study microbiology